Cargando…

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors

Chronic lymphocytic leukemia (CLL) is an incurable disease characterized by an intense trafficking of the leukemic cells between the peripheral blood and lymphoid tissues. It is known that the ability of lymphocytes to recirculate strongly depends on their capability to rapidly rearrange their cytos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampietro, Marta, Cassina, Valeria, Salerno, Domenico, Barbaglio, Federica, Buglione, Enrico, Marrano, Claudia Adriana, Campanile, Riccardo, Scarfò, Lydia, Biedenweg, Doreen, Fregin, Bob, Zamai, Moreno, Díaz Torres, Alfonsa, Labrador Cantarero, Veronica, Ghia, Paolo, Otto, Oliver, Mantegazza, Francesco, Caiolfa, Valeria R., Scielzo, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365208/ https://www.ncbi.nlm.nih.gov/pubmed/37492437 http://dx.doi.org/10.1097/HS9.0000000000000931

Ejemplares similares

3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells
por: Sampietro, Marta, et al.
Publicado: (2021)

Nanomechanics of G-quadruplexes within the promoter of the KIT oncogene
por: Buglione, Enrico, et al.
Publicado: (2021)

Nanomechanics of negatively supercoiled diaminopurine-substituted DNA
por: Salerno, Domenico, et al.
Publicado: (2021)

Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents
por: Barbaglio, Federica, et al.
Publicado: (2020)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Magnetic tweezers measurements of the nanomechanical properties of DNA in the presence of drugs
por: Salerno, Domenico, et al.
Publicado: (2010)

PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target
por: Sbrana, Francesca Vittoria, et al.
Publicado: (2023)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Magnetic tweezers measurements of the nanomechanical stability of DNA against denaturation at various conditions of pH and ionic strength
por: Tempestini, Alessia, et al.
Publicado: (2013)

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Establishment and Characterization of PCL12, a Novel CD5(+) Chronic Lymphocytic Leukaemia Cell Line
por: Agathangelidis, Andreas, et al.
Publicado: (2015)

Double-stranded flanking ends affect the folding kinetics and conformational equilibrium of G-quadruplexes forming sequences within the promoter of KIT oncogene
por: Vesco, Guglielmo, et al.
Publicado: (2021)

Interpretation of cell mechanical experiments in microfluidic systems depend on the choice of cellular shape descriptors
por: Fregin, Bob, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells
por: Sbrana, Francesca Vittoria, et al.
Publicado: (2021)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system
por: Belloni, Daniela, et al.
Publicado: (2022)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2020)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

CLL and COVID-19: light at the end of the tunnel?
por: Scarfò, Lydia, et al.
Publicado: (2022)

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Assessing Patients’ Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece
por: Karamanidou, Christina, et al.
Publicado: (2021)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia
por: McMahon, Kaylin M., et al.
Publicado: (2017)

Depicting Conformational Ensembles of α-Synuclein by Single Molecule Force Spectroscopy and Native Mass Spectroscopy
por: Corti, Roberta, et al.
Publicado: (2019)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vnsh0jm1mo0m06dm1r2ugevuon